MAPT and neurodegenerative disease: Tau pathology in the LC has been found earlier than in other brain regions during the preclinical stages of the disease [20,22,23,24,25,26], and reduced volume of the LC has been associated with the extent of beta-amyloid and tau pathologies [27,28,29], suggesting it as possible biomarker of neurodegenerative diseases [30].